Literature DB >> 30753099

Vaccine efficacy of a Mycobacterium tuberculosis Beijing-specific proline-glutamic acid (PE) antigen against highly virulent outbreak isolates.

Kee Woong Kwon1, Hong-Hee Choi1, Seung Jung Han1, Jong-Seok Kim1,2, Woo Sik Kim1,3, Hongmin Kim1, Lee-Han Kim1, Soon Myung Kang1, Jaehun Park1, Sung Jae Shin1.   

Abstract

Bacillus Calmette-Guerin vaccine confers insufficient pulmonary protection against tuberculosis (TB), particularly the Mycobacterium tuberculosis (Mtb) Beijing strain infection. Identification of vaccine antigens (Ags) by considering Mtb genetic diversity is crucial for the development of improved TB vaccine. MTBK_20640, a new Beijing genotype-specific proline-glutamic acid-family Ag, was identified by comparative genomic analysis. Its immunologic features were characterized by evaluating interactions with dendritic cells (DCs), and immunogenicity and vaccine efficacy were determined against highly virulent Mtb Beijing outbreak Korean Beijing (K) strain and HN878 strain in murine infection model. MTBK_20640 induced DCs via TLR2 and downstream MAPK and NF-κB signaling pathways, effectively promoting naive CD4-positive (CD4+) T-cell proliferation and IFN-γ production. Different IFN-γ response was observed in mice infected with Mtb K or reference H37Rv strain. Significant induction of T helper type 1 cell-polarized Ag-specific multifunctional CD4+ T cells and a marked Ag-specific IgG2c response were observed in mice immunized with MTBK_20640/glucopyranosyl lipid adjuvant-stable emulsion. The immunization conferred long-term protection against 2 Mtb Beijing outbreak strains, as evidenced by a significant reduction in colony-forming units in the lung and spleen and reduced lung inflammation. MTBK_20640 vaccination conferred long-term protection against highly virulent Mtb Beijing strains. MTBK_20640 may be developed into a novel Ag component in multisubunit TB vaccines in the future.-Kwon, K. W., Choi, H.-H., Han, S. J., Kim, J.-S., Kim, W. S., Kim, H., Kim, L.-H., Kang, S. M., Park, J., Shin, S. J. Vaccine efficacy of a Mycobacterium tuberculosis Beijing-specific proline-glutamic acid (PE) antigen against highly virulent outbreak isolates.

Entities:  

Keywords:  Beijing genotype; MTBK_20640; dendritic cells; subunit vaccine

Year:  2019        PMID: 30753099     DOI: 10.1096/fj.201802604R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  5 in total

1.  Novel Antibacterial Activity of Febuxostat, an FDA-Approved Antigout Drug against Mycobacterium tuberculosis Infection.

Authors:  Lee-Han Kim; Soon Myung Kang; Jake Whang; Kee Woong Kwon; Sung Jae Shin
Journal:  Antimicrob Agents Chemother       Date:  2022-08-30       Impact factor: 5.938

2.  Viral coinfection promotes tuberculosis immunopathogenesis by type I IFN signaling-dependent impediment of Th1 cell pulmonary influx.

Authors:  Tae Gun Kang; Kee Woong Kwon; Kyungsoo Kim; Insuk Lee; Myeong Joon Kim; Sang-Jun Ha; Sung Jae Shin
Journal:  Nat Commun       Date:  2022-06-07       Impact factor: 17.694

Review 3.  Pathological and protective roles of dendritic cells in Mycobacterium tuberculosis infection: Interaction between host immune responses and pathogen evasion.

Authors:  Hongmin Kim; Sung Jae Shin
Journal:  Front Cell Infect Microbiol       Date:  2022-07-28       Impact factor: 6.073

4.  Antigen-Specific IFN-γ/IL-17-Co-Producing CD4+ T-Cells Are the Determinants for Protective Efficacy of Tuberculosis Subunit Vaccine.

Authors:  Han-Gyu Choi; Kee Woong Kwon; Seunga Choi; Yong Woo Back; Hye-Soo Park; Soon Myung Kang; Eunsol Choi; Sung Jae Shin; Hwa-Jung Kim
Journal:  Vaccines (Basel)       Date:  2020-06-11

5.  Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model.

Authors:  Kee Woong Kwon; Ara Lee; Sasha E Larsen; Susan L Baldwin; Rhea N Coler; Steven G Reed; Sang-Nae Cho; Sang-Jun Ha; Sung Jae Shin
Journal:  Sci Rep       Date:  2019-10-29       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.